Comparison of Efficacy on First-Line Helicobacter Pylori Eradication Between Potassium-Competitive Acid Blocker (P-CAB)-Based Therapies Versus Proton-Pump Inhibitor (PPI)-Based Therapies
Vonoprazan-based triple therapy has a higher eradication rate than PPI-based triple therapies, as well as other P-CABs based regimens. It remains unclear whether VAC7 is superior over vonoprazan-based dual therapy (VA7). Overall, VAC7 should be recommended for clinical and public health interventions, with VA7 as a possible alternative considering the local antimicrobial resistance profiles.
Authors
- Heng Jiang (ORCID: https://orcid.org/0000-0001-8394-6077)
- Xiaoyu Wan (ORCID: https://orcid.org/0000-0002-5587-9353)
- Kangning Peng (ORCID: https://orcid.org/0009-0002-2693-1615)
Institutions
- Cambridge Health Alliance (US)
- Westchester Medical Center (US)
- Harvard University (US)
- Hong Kong Polytechnic University (HK)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1097/mcg.0000000000002190
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00